Geriatric Chronic Heart Failure with Preserved Ejection Fraction

Clinical Guide: Geriatric Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)

1. Comprehensive Introduction & Overview

Heart Failure with Preserved Ejection Fraction (HFpEF), historically referred to as "diastolic heart failure," has emerged as the dominant phenotype of heart failure in the geriatric population. Defined by the presence of clinical heart failure symptoms and signs alongside a left ventricular ejection fraction (LVEF) of ≥50%, it represents a complex syndrome of multisystem involvement.

In geriatric patients, HFpEF is rarely an isolated cardiac pathology. It is frequently the manifestation of a "geriatric syndrome," characterized by high levels of comorbidity, frailty, cognitive impairment, and polypharmacy. Unlike Heart Failure with Reduced Ejection Fraction (HFrEF), which is often driven by coronary artery disease and myocardial infarction, HFpEF is driven by chronic systemic inflammation, microvascular dysfunction, and age-related remodeling of the myocardium.

2. Pathophysiology and Etiology

The pathophysiology of HFpEF in the elderly is multifactorial and distinct from younger cohorts.

The "Inflammatory-Comorbidity" Model

Recent consensus suggests that HFpEF is driven by a systemic inflammatory state induced by comorbidities such as obesity, hypertension, diabetes mellitus, chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). This inflammation leads to:
* Coronary Microvascular Dysfunction: Reduced nitric oxide bioavailability leads to impaired cyclic guanosine monophosphate (cGMP) signaling in cardiomyocytes, resulting in increased stiffness and impaired relaxation.
* Myocardial Fibrosis: Activation of fibroblasts leads to extracellular matrix deposition, increasing ventricular stiffness.
* Diastolic Dysfunction: The inability of the ventricle to relax and fill appropriately at low pressures, leading to elevated left ventricular end-diastolic pressure (LVEDP).

Etiological Drivers in the Elderly

3. Clinical Presentation and Staging

Standard Presentation

Geriatric patients often present with non-specific symptoms, which frequently leads to diagnostic delays.
* Exertional Dyspnea: Often misattributed to "being out of shape" or pulmonary disease.
* Fatigue: A cardinal symptom in the elderly.
* Peripheral Edema: Can be confounded by venous insufficiency or hypoalbuminemia.
* Orthopnea and PND: Often absent in early stages or masked by sedentary behavior.

Clinical Staging (H2FPEF Score)

To improve diagnostic accuracy, clinicians utilize the H2FPEF score to estimate the probability of HFpEF:
* Heavy (BMI >30 kg/m²)
* Hypertensive (≥2 antihypertensives)
* Atrial fibrillation (Paroxysmal or persistent)
* Pulmonary hypertension (PASP >35 mmHg)
* Elderly (>60 years)
* Filling pressures (E/e' >9)

4. Differential Diagnosis

Differentiating HFpEF from other causes of dyspnea in the elderly is critical:
1. Pulmonary Disease: COPD and interstitial lung disease often coexist with HFpEF.
2. Valvular Heart Disease: Specifically aortic stenosis, which can mimic HFpEF symptoms.
3. Cardiac Amyloidosis: Increasingly recognized in patients >75 years; requires high index of suspicion (low voltage on ECG, thickened ventricular walls on Echo).
4. Anemia: Often exacerbates symptoms of heart failure.
5. Obesity: Can mimic the signs of congestion.

5. Diagnostic Testing Protocols

A systematic approach is required to confirm the diagnosis according to the HFA-PEFF algorithm.

Key Diagnostic Steps

• Echocardiography: Gold standard for assessing diastolic function (E/e' ratio, left atrial volume index, tricuspid regurgitation velocity).
• Natriuretic Peptides (NT-proBNP/BNP): While sensitive, levels can be lower in obese geriatric patients; however, elevated levels support the diagnosis.
• Stress Testing (Exercise Echo): Often necessary if resting echocardiography is inconclusive, to unmask diastolic dysfunction under physiological stress.
• Cardiac MRI: Useful for identifying myocardial fibrosis or infiltrative diseases (amyloidosis).

6. Management Strategies

Management in the elderly focuses on symptom relief, reduction of hospitalizations, and preservation of functional status.

Pharmacological Interventions

1. SGLT2 Inhibitors: The cornerstone of modern HFpEF management (e.g., Empagliflozin, Dapagliflozin). They reduce the risk of hospitalization regardless of diabetes status.
2. Diuretics: Essential for managing volume overload. Use with caution to avoid hypotension and renal impairment (AKI).
3. Mineralocorticoid Receptor Antagonists (MRAs): Beneficial in selected patients to reduce fibrosis and hospital readmission.
4. Blood Pressure Management: Target systolic BP <130 mmHg, but maintain caution in the "frail" elderly to avoid orthostatic hypotension.

Non-Pharmacological Management

• Cardiac Rehabilitation: Highly recommended to improve exercise tolerance.
• Dietary Sodium Restriction: Aim for <2g/day.
• Vaccination: Influenza and Pneumococcal vaccines are mandatory to prevent exacerbations.

7. Risks, Side Effects, and Contraindications

Geriatric patients are at high risk for adverse drug events (ADEs).
* Diuretic Overuse: Leads to electrolyte imbalances (hypokalemia, hyponatremia) and acute kidney injury.
* Polypharmacy: Careful review of medication lists is necessary to avoid "prescribing cascades."
* Beta-Blockers: While standard in HFrEF, they provide no mortality benefit in HFpEF and may exacerbate bradycardia or fatigue in the elderly. Use only for rate control in AFib.

8. Long-Term Prognosis

HFpEF in the elderly is associated with significant morbidity. The 5-year mortality rate remains high, often exceeding 50%. Prognosis is largely dictated by:
* Functional Frailty: The strongest predictor of mortality.
* Renal Function: Worsening eGFR is a negative prognostic indicator.
* Cognitive Status: Dementia limits the ability to adhere to complex medication regimens.

9. Frequently Asked Questions (FAQ)

1. Is HFpEF the same as diastolic heart failure?

Yes, the term "diastolic heart failure" was the historical name. HFpEF is the modern, more precise term reflecting that the issue is not just relaxation (diastole) but also vascular stiffness and systemic inflammation.

2. Can HFpEF be cured?

Currently, there is no cure, but it is a manageable chronic condition. With the advent of SGLT2 inhibitors and structured exercise programs, patients can experience significant improvements in quality of life.

3. Why are my NT-proBNP levels "normal" despite heart failure symptoms?

In patients with high BMI, natriuretic peptide levels are often lower than expected. A "normal" result in an obese patient does not definitively rule out HFpEF.

4. Should I be on a beta-blocker for my HFpEF?

Only if you have an additional indication, such as Atrial Fibrillation or angina. Unlike HFrEF, beta-blockers do not improve survival in pure HFpEF and may cause fatigue.

5. What is the role of exercise in HFpEF?

Exercise is vital. It improves endothelial function, reduces systemic inflammation, and increases peak oxygen consumption (VO2 peak). It is one of the most effective non-pharmacological interventions.

6. How does kidney disease affect HFpEF treatment?

CKD is a common comorbidity. It limits the use of certain medications (like high-dose spironolactone) and increases the risk of AKI when using diuretics. Close monitoring of creatinine and electrolytes is essential.

7. Does HFpEF progress to HFrEF?

While some patients experience a decline in ejection fraction over time, most patients with HFpEF remain within the "preserved" range throughout their disease course.

8. What is the most common cause of death in HFpEF patients?

While cardiovascular death is common, many geriatric patients with HFpEF die from non-cardiovascular causes, including infections and complications of frailty.

9. How often should I have an echocardiogram?

There is no fixed schedule. An echo is indicated at diagnosis and if there is a significant change in clinical status or a new arrhythmia.

10. Can SGLT2 inhibitors be used if I am not diabetic?

Yes. Recent landmark trials (EMPEROR-Preserved, DELIVER) have demonstrated that SGLT2 inhibitors reduce hospitalization for heart failure in patients with HFpEF regardless of their glycemic status.

11. Conclusion

Managing Geriatric HFpEF requires a transition from a "disease-centered" approach to a "patient-centered" approach. By integrating SGLT2 inhibitor therapy, aggressive comorbidity management, and a focus on physical function, clinicians can significantly improve the quality of life for this vulnerable population. Early identification and a multidisciplinary team approach—involving cardiology, geriatrics, and physical therapy—remain the gold standard for clinical excellence in this domain.